Study | Study Characteristics | Assessment of the risk of bias | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Population | Nb | % Male | Baseline CD4 | Baseline VL | Follow-up time | Eligibility | HSV-2 Ascertain-ment | Endpoints | Confoun-ding | Analysis | Attrition | OVERALL | Impact of biasc | |
Barnabas 2011 | Men, International | 88 | 100 | NR | NR | NR | Moderate | Low | Low | Moderate | Moderate | Moderate | Moderate | ↓ |
Cachay 2007 | Male HIV seroconverters, USA | 294 | 100 | 497 | 4.97 | 205 days | Low | Low | Low | Low | Moderate | Low | Low | N/A |
Cachay 2008 | Male HIV seroconverters, USA | 119 | 100 | 520 | 5.04 | 779 days | Low | Low | Moderate | Low | Moderate | Low | Low | N/A |
Crum-Cianflone 2006 | USA | 367 | 92 | 499 | NR | NR | Low | Moderate | Moderate | High | Moderate | Moderate | High | ? |
Nagot 2008 | Women, Burkina Faso | 140 | 0 | 443 | 4.48 | 12 weeks | Moderate | Low | Low | Low | Moderate | Low | Low | N/A |
Roxby 2011 | Pregnant women, Kenya | 296 | 0 | 422 | 4.75 | 18 months | Moderate | Low | Low | Moderate | Moderate | Moderate | Moderate | ↓ |
Suligoi 2001 | HIV sero-converters, Italy | 380 | 78 | NR | NR | 7.8 years | Low | Low | Moderate | High | Moderate | High | High | ? |